en بررسی عوامل موثر بر فاکتورهای 9 و10 د ر بیماران هموفیلی در استان کرمانشاه Adults Hematology & Oncology Adults Hematology & Oncology پژوهشي Original Article <p> </p> <div style="direction: ltr"><span style="line-height: 1.6em">Background: Hemophilia is the most frequent severe hereditary hemorrhagic disease due to deficiency of coagulation factors VIII (Hemophilia A) or IX (Hemophilia B) in plasma. We aimed to identify patients with  hemophilia in Kermanshah, Iran and assess the incidence of inhibitors in this population and its associated factors.</span></div> <div style="direction: ltr"><span style="line-height: 1.6em">Methods: This study was conducted on patients with hemophilia A and B admitted in hospitals of Kermanshah city, referred to coagulation laboratory of Kermanshah blood transfusion organization. Variables including age, sex, family history of the patients in terms of history of hemophilia and inhibitor formation, development of inhibitor in patients, age at starting the treatment, blood group, severity of hemophilia, average of factors received per month and liver disease were assessed in patients.</span></div> <div style="direction: ltr"><span style="line-height: 1.6em">Results: Of 123 patients with hemophilia A, 119 (96.7%) were men. The mean±SD age of patients with hemophilia A was 25.9±15.74 years. Only five men had developed factor VIII inhibitor. Of 25 patients with hemophilia B, 24 (96%) were men with a mean±SD age of 21.7±15.71 years. Factor IX inhibitor was not detected in any patient. There was no association between incidence of inhibitors and age at the onset of the treatment, family history of hemophilia, blood group, severity of hemophilia, average of received factor per month and liver disease. However, a positive association between incidence of inhibitors and family history of inhibitors was found (P<0.05).</span></div> <div style="direction: ltr"><span style="line-height: 1.6em">Conclusion: Association between family history of inhibitor and incidence of inhibitor formation in hemophilic patients was a new finding. Therefore this outcome and genetic evaluation of these for finding relevant mutations should be considered.</span></div> Factor VIII, Factor IX, Hemophilia A, Hemophilia B, Inhibitorو Predisposing factor, Genetic mutation, Severity of disease 191 194 http://ijbc.ir/browse.php?a_code=A-10-218-7&slc_lang=en&sid=1 M Payandeh md.payandeh@yahoo.com 10031947532846003096 10031947532846003096 No Department of Hematology and Medical Oncology, Kermanshah University of Medical Sciences, Kermanshah, Iran N Amirifard 10031947532846003100 10031947532846003100 No E Sadeghi sadeghi_mkn@yahoo.com 10031947532846003098 10031947532846003098 Yes Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran M Sadeghi sadeghi_mbrc@yahoo.com 10031947532846003097 10031947532846003097 No Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran M Choubsaz 10031947532846003101 10031947532846003101 No F Noor Mohammadi Far 10031947532846003099 10031947532846003099 No Students Research Committee, Kermanshah University of Medical Sciences, Kermanshah, Iran mehrnoush.aeinfar@gmail.com 10031947532846003102 10031947532846003102 No